Vela Diagnostics has added two SARS-CoV-2 assays to its portfolio: ViroKey SQ Flex SARS-CoV-2 genotyping and ViroKey SARS-CoV-2 ID reverse transcription polymerase chain reaction (RT-PCR).
The genotyping assay uses next-generation sequencing (NGS) to sequence the entire SARS-CoV-2 genome in less than two hours, the company said. The accompanying Sentosa SQ Reporter software then calls out mutations and classifies them by lineage, aiding research into and understanding of the novel coronavirus.
Vela Diagnostics' RT-PCR assay is able to identify COVID-19 variants including B.1.1.7 stemming from the U.K., B.1.351 from South Africa, and P.1 from Brazil. The variant identification test can be paired with the ViroKey SARS-CoV-2 RT-PCR test v2.0, which has received U.S. Food and Drug Administration (FDA) emergency use authorization (EUA), Europe's CE-IVD Mark, Australian Therapeutic Goods Administration (TGA) approval, and Singapore's Health Sciences Authority (HSA) provisional authorization.
Both of the new assays are for research use only, the company noted.